宫颈癌是女性常见恶性肿瘤之一。针对局部晚期及复发转移的宫颈癌患者尚未有令人满意的治疗手段，因此探索和发展更有效的治疗方案具有重要的意义。PI3K/AKT/mTOR信号通路在人类子宫颈癌细胞的增殖、分化和凋亡中具有重要的调节作用，有希望成为开发宫颈癌治疗药物的新型靶标。综述了近年来PI3K/AKT/mTOR信号通路的单一及双重靶点抑制剂针对宫颈癌的临床前及临床研究情况，包括PI3K抑制剂（wortmannin、LY294002、吲哚-3-甲醇）、AKT抑制剂（SC-66、MK-2206、木黄酮、冬凌草甲素和雷公藤）、mTOR抑制剂（替西罗莫司和依维莫司）及双重靶点抑制剂（GSK2126458、BEZ235、BGT226、PF04691502、GDC-0980和PKI-587）等。

Cervical cancer is a common malignant tumor of women all over the world. There is no satisfactory treatment for cervical cancer patients with locally advanced and recurrent metastases. Therefore, it is of great significance to explore and develop more effective treatment protocols. The PI3K/AKT/mTOR signaling pathway plays an important regulatory role in the proliferation, differentiation, and apoptosis of human cervical cancer cells, and it is hopeful that it will become a new target for the development of therapeutic drugs for cervical cancer. Therefore, preclinical and clinical research on single and dual target inhibitors of cervical cancer on PI3K/AKT/mTOR signaling pathway in this pathway are reviewed in recent years. The inhibitors include PI3K inhibitors (wortmannin, LY294002, and indole-3-methanol), AKT inhibitors (SC-66, MK-2206, flavonoids, oridonide, and tripterygium wilfordii), mTOR inhibitors (CCI-779 and RAD-001), and dual inhibitors (GSK2126458, BEZ235, BGT226, PF04691502, GDC-0980, and PKI-587).

首都医科大学附属北京妇产医院中青年学科骨干培养专项（fcyy201608）；首都医科大学2017年基础-临床科研合作基金资助项目（17JL38）